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Abstract 
Akkermansia muciniphila is an anaerobic species of gut microbiome that has been proposed as a new 
functional microbiota with probiotic properties. Recent research has shown the amazing abilities of 
probiotic bacteria, A. muciniphila, which resides in most people's intestines. These bacteria affect the 
body if it increases or decreases abdominal fat. The presence of A. muciniphila has opened new ways 
for the use of this plentiful intestinal symbiont in next generation therapeutic products, as well as 
targeting microbiota dynamics. A. muciniphila is particularly effective in increasing mucosal thickness 
and enhancing bowel barrier function. As a result, host metabolic markers improve. The host functions 
that are disrupted in various diseases with a particular focus on metabolic disorders in animals and 
humans. A specific protein in the outer membrane of A. muciniphila called Amuc-110 could in the 
future be a strong candidate for drug production. As a result, we suggest that microbes and our 
microbiology or gut microbiome knowledge could be a new source for future treatments. The objectives 
of this review are to summarize the data available on the distribution of A. muciniphila gut in health 
and disease, to provide insights into the environment and its role in the creation of microbial networks 
at the mucosal interface, as well as to discuss recent research on its role in regulation. 
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Introduction 
Akkermansia was introduced by Dutch 
microbiologist Anton Akkermansia (born October 28, 
1940: died August 21, 2006) who studies the biology of 
microorganisms. This genus contains a single species 
called Akkermansia muciniphila [1]. The word mucio 
is derived from the Latin root of mucin in the 
gastrointestinal tract and phila is derived from the 
Latin word filos. Muciniphila also calls mucin an 
inhibitor. A. muciniphila is a dominant human 
intestinal mucin-degrading bacterium in a genus 
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proposed in 2004 by Muriel Derrien and colleagues.  
It’s a Gram-negative, oval-shaped, strictly anaerobic, 
non-motile non-spore-former. Odd that such an 
abundant organism had to wait so long to be 
discovered. Probably this has to do with the conditions 
used to its isolation, which is an anaerobic medium 
containing gastric mucin as the only carbon and 
nitrogen source. The genus Akkermansia belongs to 
the division Verrucomicrobia [2,3]. 
Microbial ecosystem of A. muciniphila 
Most likely, there is a relationship between fecal
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microbiota and health indicators. Not just a pure 
microorganism but an ecosystem that restores the 
complex balance between host biology and the 
environment. According to the abundant study of A. 
muciniphila, it is related to extensive metagenomics 
frequency and abundance of bacterial genes [4]. 
Role of A. muciniphila in obesity and type 
2 diabetes 
Obesity-related metabolic disorders and cardiac 
metabolism are widespread worldwide. Among all 
environmental factors, the intestinal microbiota is 
now an important intervention in host energy and 
metabolism that is susceptible to several non-
communicable diseases [5]. Among the next-
generation bacteria that appear to be useful, A. 
muciniphila is the future candidate. Without a doubt, 
A. muciniphila is inversely related to obesity, diabetes, 
cardiovascular disease and superficial inflammation 
[2]. Gut microbiota and its changes in the composition 
and biodiversity, can play an appropriate role in the 
expansion of metabolic diseases. In humans, most of 
the papers show that a depauperated microbial 
diversity is associated with a higher insulin resistance, 
obesity and inflammation Although oral 
administration of A. muciniphila to mice fed with 
high-fat diet (HFD) extremely improves glucose 
homeostasis, the antidiabetic properties of this 
bacterium have not been indicated in humans because 
of its growth properties and oxygen sensitivity that set 
the use of living A. muciniphila improper for putative 
therapeutic chances. [6]. In addition, numerous 
documents have shown that pasteurization of A. 
muciniphila increases both stability and efficiency of 
strains [7]. This gives you the powerful A. muciniphila 
as the next generation of candidates to produce new 
foods or medicinal supplements with beneficial 
properties. Finally, a specific protein in the outer 
membrane of A. muciniphila, called Amuc_1100, 
which is one of the most abundant proteins involved in 
pellet formation, can be a powerful candidate for the 
production of subsequent drugs [8-11]. We suggest 
that microbes and microbiology, or our gut 
microbiome knowledge, could be a new source for 
future treatments. Obesity provides the basis for 
developing type 2 diabetes and cardiovascular disease. 
These two pathologies are part of the metabolic 
syndrome. It is also an important issue in public health 
[7]. Intestinal microbes play a vital part in regulating 
host metabolism and surface inflammation. Several 
researches have shown that our eating lifestyles greatly 
impact the composition and function of the gut 
microbiota and may ultimately play a role in initiating 
or protecting against metabolic disorders [12,13]. 
From peribiotics to next-generation 
beneficial microbes: focus on identifying A. 
muciniphila 
One possible way to influence the intestinal 
microbiota, which is well documented, is to use 
selected microbes that market the host health benefits 
to the host by defining "living microorganisms that are 
used properly." Other methods, such as the use of 
probiotics over the past 20 years, have received much 
attention [14]. The concept of prebiotics, first observed 
by Gibson and Rutherford (1995), has led to a large 
number of dietary supplements, leading to significant 
market growth [15]. Peribiotics are the selective 
stimulation of the growth or activity of one or a limited 
number of microbial genera (species) or species in the 
gut microbiota that provide health benefits to the host 
[16]. According to the methodological and 
fundamental research of microbiologists, there has 
been a great deal of progress recently in our 
understanding of gut microbiota. However, the subject 
of peribiotics has not fully understood. Despite various 
research on the molecular mechanisms underlying 
how prebiotics and intestinal microbes interact with 
the host, the identification of the candidate bacterium 
elaborate in useful effects on energy, glucose, lipid 
metabolism and immunity is still difficult [17]. A. 
muciniphila is one of the most abundant single species 
in the human gut microbiota (0.5% - 0.5% of total 
bacteria) and in 2004 by Maurice Drine in his doctoral 
research at the University of Wageningen as a 
specialist in the use of the distinct and Specific Mucus 
[18, 19] The discovery began with the fact that the 
human body produces "Peribiotics" or microbial layers 
called mucus (sputum), which is a glycoprotein and 
offspring especially in the large intestine that destroy it 
goes [20]. While experiments on non-microbial mice 
have shown that A. muciniphila shows immunity and 
metabolic signaling, especially in the colon, the exact 
function of these microbes is unclear [21, 22]. Further 
evidence of the function of A. muciniphila has been 
repeatedly identified by other prebiotic studies using 
inulin-type fructans, initially known as bifidogenic 
compounds that can increase the quantity of 
Bifidobacterium species. They thanked the 
development of new techniques independent of 
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culture. The study investigated the effect of this type of 
prebiotics on a microbial complex in mice [23]. The 
first surprise was that more than 100 different species 
were affected by prebiotics [14]. Among these bacteria, 
they found that the relative abundance of A. 
muciniphila increased more than 100-fold after 
peribiotic intake and reached more than 4.5% in high-
fat diets, whereas this effect on a normal diet (2.5% - 
0.09) was less in his model [22]. Notably, these 
findings are approved in different sets of studies [23, 
24]. Some studies show that A. muciniphila was lower 
in the gut microbiota of diabetic rats and mice that 
were genetically or affected by obese diets. However, 
few studies have reported the frequency of A. 
muciniphila in mice with increased glucose and fat 
intake [15]. Insulin-rich fructans have also been widely 
shown to show obesity-related metabolic disorders, 
including fat mass depletion, insulin resistance, 
hepatic steatosis, and intestinal barrier strengthening 
[25]. Importantly, in humans, the frequency of A. 
muciniphila has been reduced in several pathological 
conditions, including obesity, type 2 diabetes, 
gastrointestinal inflammation, hypertension, and 
intestinal disease [26, 27]. On the other hand, it has 
been found that antidiabetic therapies, such as the use 
of metformin and bariatric surgery, are associated with 
a significant increase in mucosal levels. Thus, much 
evidence has been shown that A. muciniphila can 
protect against specific metabolic disorders and risk 
factors for cardiovascular metabolism associated with 
a low degree of inflammation [28]. 
The role of A. muciniphila on and around 
the intestine 
The gut microbiota is the largest human microbial 
reservoir that has a prominent role in human health 
and is involved in regulating many host physiological 
pathways such as regulating gastrointestinal 
stimulation, digestive barrier permeability, lipid 
distribution, and energy homeostasis [5]. A great deal 
of data suggesting the relative frequency of A. 
muciniphila in obesity and metabolic disorders in 
mice and humans, we decided to investigate the usual 
association between A. muciniphila and metabolic 
enhancers [2, 5, 29]. Carlota Dao et al found that the 
use of A. muciniphila, a live fillet with 2.108 bacterial 
cells per day, partially protected diet-induced obesity 
in mice [2]. Certainly, when dietary intake was not 
altered or dietary fat was removed, rats had a 50% 
lower weight gain treated with the live drug A. 
muciniphila. This protection is reflected by less 
subcutaneous and internal fat mass as well as by 
increased markers of fatty acid oxidation (Acox1, 
Cpt1a, Acacb) in adipose tissue [30, 31]. In addition, 
animals treated with the live A. muciniphila substrate 
no longer showed insulin resistance, infiltrating 
inflammatory cells (CD11c) in adipose tissue which is 
one of the most important features of obesity-
associated with superficial inflammation [32]. 
Interestingly, the metabolic improvements following 
the administration of live A. muciniphila were 
comparable with results obtained from the treatment 
with oligofructose or inulin [30, 32]. However, live A. 
muciniphila did not mimic prebiotics food intake 
behaviors. There is also a great interest in A. 
muciniphila because of its association with animal and 
human health. Remarkably, decreased levels of A. 
muciniphila have been observed in patients with 
inflammatory bowel disease (mainly ulcerative colitis) 
and metabolic disorders, suggesting that they may 
have potential anti-inflammatory properties  [5 ,33.]  
Conclusion 
Several studies have shown that A. muciniphila 
can reduce the serum level of inflammatory cytokines 
like IL-2, IFN-γ, IL-12p40, and MCP-1, and also the 
lipid overload process linked with the LDL receptor 
pathway by decreasing apoB48 and apoB100 on 
LDLs. Meanwhile, A. muciniphila can modulate the 
immune system by production of short-chain fatty 
acid which is elaborate in signaling to the host by 
inhibiting histone deacetylase (HDAC) or by activating 
G-protein-coupled receptors, which triggers other 
metabolic pathways [34,36]. The main steps towards 
the growth of A. muciniphila as a new probiotic 
candidate have been completed. Initially, the 
identification of A. muciniphila being grown on a 
defined medium according to performance in 
humans. Second, it has been found that inactivation of 
the bacteria by pasteurization improves its stability 
and durability. Third, Amuc_1100 introduced as a key 
mechanism of interaction between A. muciniphila and 
its host. Fourth, the evidence that A. muciniphila may 
be safely managed in the targeted people [9, 17, 35]. 
Eventually, the pasteurized bacteria and the isolation 
of bacterial components like the fairly small 30-kDa 
Amuc_1100 cause to putative progress of drugs based 
on A. muciniphila related products that could target 
inflammatory bowel disease or diseases that 
compromise the function of the bowel barriers [33]. As 
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a result, comprehensive information on A. 
muciniphila has become progressively available, and 
many of the criteria set for evaluating novel food safety 
in Europe can be fulfilled. However, no studies on the 
toxicological properties of A. muciniphila, including 
dose-response studies, long-term studies, and 
reproduction, have been published so far. Such studies 
are likely to be important before authorities complete 
a comprehensive safety assessment. 
Author Contributions 
 All authors contributed equally to this manuscript 
and approved the final version of manuscripts . 
Conflict of Interests  
The authors declare that they have no conflicts of 
interest . 
Ethical declarations  





1. Euzéby JP. List of Bacterial Names with Standing in 
Nomenclature: a folder available on the Internet. Int J Syst Evol 
Microbiol. 1997;47(2):590-2. 
2. Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, 
Verger EO, et al. Akkermansia muciniphila and improved 
metabolic health during a dietary intervention in obesity: 
relationship with gut microbiome richness and ecology. Gut. 
2016;65(3):426-36. 
3. Gómez-Gallego C, Pohl S, Salminen S, De Vos W, Kneifel W. 
Akkermansia muciniphila: a novel functional microbe with 
probiotic properties. Benef Microbes. 2016;7(4):571-84. 
4. Zhou K. Strategies to promote abundance of Akkermansia 
muciniphila, an emerging probiotics in the gut, evidence from 
dietary intervention studies. J Funct Foods. 2017;33:194-201. 
5. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels 
LB, et al. Cross-talk between Akkermansia muciniphila and 
intestinal epithelium controls diet-induced obesity. Proc Natl Acad 
Sci. 2013;110(22):9066-71. 
6. Depommier C, Everard A, Druart C, Plovier H, Van Hul M, 
Vieira-Silva S, et al. Supplementation with Akkermansia 
muciniphila in overweight and obese human volunteers: a proof-
of-concept exploratory study. Nat Med. 2019;25(7):1096-103. 
7. Plovier H, Everard A, Druart C, Depommier C, Van Hul M, 
Geurts L, et al. A purified membrane protein from Akkermansia 
muciniphila or the pasteurized bacterium improves metabolism in 
obese and diabetic mice. Nat Med. 2017;23(1):107-13. 
8. Belzer C, De Vos WM, Cani PD. Use of a polypeptide for effecting 
immune signalling and/or affecting intestinal barrier function 
and/or modulating metabolic status. Google Patents; 2018. 
9. Naito Y, Uchiyama K, Takagi T. A next-generation beneficial 
microbe: Akkermansia muciniphila. J Clin Biochem Nutr. 
2018;63(1):33-5. 
10. Roubalová R, Procházková P, Papežová H, Smitka K, Bilej M, 
Tlaskalová-Hogenová H. Anorexia nervosa: Gut microbiota-
immune-brain interactions. Clinical Nutrition. 2020;39(3):676-
84. 
11. Seebeck T, Chen F, Davis GD. Engineered cas9 systems for 
eukaryotic genome modification. Google Patents; 2019. 
12. Cheng P, Yao L, Chen X, Su X, Su X, Huang Q, et al. An 
inflammatory memory and angiogenic self-assembling nanofiber 
hydrogel scaffold seeded with Akkermansia muciniphila to 
accelerate the healing of diabetic ischemic ulcers. RSC Adv. 
2018;8(31):17357-64. 
13. Remely M, Hippe B, Zanner J, Aumueller E, Brath H, G 
Haslberger A. Gut microbiota of obese, type 2 diabetic individuals 
is enriched in Faecalibacterium prausnitzii, Akkermansia 
muciniphila and Peptostreptococcus anaerobius after weight loss. 
Endocr Metab Immune Disord Drug Targets. 2016;16(2):99-106. 
14. Cani PD, de Vos WM. Next-generation beneficial microbes: the 
case of Akkermansia muciniphila. Front Microbiol. 2017;8:1765. 
15. Gibson GR, Roberfroid MB. Dietary modulation of the human 
colonic microbiota: introducing the concept of prebiotics. J Nutr. 
1995;125(6):1401-12. 
16. Roberfroid M. Prebiotics and synbiotics: concepts and 
nutritional properties. Br J Nutr. 1998;80(S2):S197-S202. 
17. Rostami FM, Mousavi H, Mousavi MRN, Shahsafi M. Efficacy 
of probiotics in prevention and treatment of infectious diseases. 
Clin Microbiol Newsl. 2018;40(12):97-103. 
18. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, 
et al. Metabolic endotoxemia initiates obesity and insulin 
resistance. Diabetes. 2007;56(7):1761-72. 
19. Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia 
muciniphila gen. nov., sp. nov., a human intestinal mucin-
degrading bacterium. Int J Syst Evol Microbiol. 2004;54(5):1469-
76. 
20. Ouwehand AC, Derrien M, de Vos W, Tiihonen K, Rautonen N. 
Prebiotics and other microbial substrates for gut functionality. 
Curr Opin Biotechnol. 2005;16(2):212-7. 
21. Derrien M, Collado MC, Ben-Amor K, Salminen S, de Vos WM. 
The Mucin degrader Akkermansia muciniphila is an abundant 
resident of the human intestinal tract. Appl Environ Microbiol. 
2008;74(5):1646-8. 
22. Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, 
Neyrinck AM, et al. Responses of gut microbiota and glucose and 
lipid metabolism to prebiotics in genetic obese and diet-induced 
leptin-resistant mice. Diabetes. 2011;60(11):2775-86. 
23. Everard A, Lazarevic V, Gaïa N, Johansson M, Ståhlman M, 
Backhed F, et al. Microbiome of prebiotic-treated mice reveals 
novel targets involved in host response during obesity. ISME J. 
2014;8(10):2116-30. 
24. Yan M, Song M-M, Bai R-X, Cheng S, Yan W-M. Effect of Roux-
en-Y gastric bypass surgery on intestinal Akkermansia 
muciniphila. World J Gastrointest Surg. 2016;8(4):301. 
25. Cani PD. Microbiota and metabolites in metabolic diseases. Nat 
Rev Endocrinol. 2019;15(2):69-70. 
26. Macchione I, Lopetuso L, Ianiro G, Napoli M, Gibiino G, 
Rizzatti G, et al. Akkermansia muciniphila: key player in metabolic 
and gastrointestinal disorders. Eur Rev Med Pharmacol Sci. 
2019;23(18):8075-83. 
27. Zhang L, Carmody RN, Kalariya HM, Duran RM, Moskal K, 
Poulev A, et al. Grape proanthocyanidin-induced intestinal bloom 
Mohammadzadeh Rostami et al.  
5 
 
of Akkermansia muciniphila is dependent on its baseline 
abundance and precedes activation of host genes related to 
metabolic health. J Nutr Biochem. 2018;56:142-51. 
28. Anhê FF, Pilon G, Roy D, Desjardins Y, Levy E, Marette A. 
Triggering Akkermansia with dietary polyphenols: A new weapon 
to combat the metabolic syndrome? Gut Microbes. 2016;7(2):146-
53. 
29. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut 
microbiota in the development of low-grade inflammation and 
type 2 diabetes associated with obesity. Gut Microbes. 
2012;3(4):279-88. 
30. Ganesh BP, Klopfleisch R, Loh G, Blaut M. Commensal 
Akkermansia muciniphila exacerbates gut inflammation in 
Salmonella Typhimurium-infected gnotobiotic mice. PloS One. 
2013;8(9):e74963. 
31. Hutkins RW, Krumbeck JA, Bindels LB, Cani PD, Fahey Jr G, 
Goh YJ, et al. Prebiotics: why definitions matter. Curr Opin 
Biotechnol. 2016;37:1-7. 
32. Kaplan M, Mutlu EA, Benson M, Fields JZ, Banan A, 
Keshavarzian A. Use of herbal preparations in the treatment of 
oxidant-mediated inflammatory disorders. Complement Ther 
Med. 2007;15(3):207-16. 
33. Jonsson AL, Bäckhed F. Role of gut microbiota in 
atherosclerosis. Nat Rev Cardiol. 2017; 14(2):79-87. 
34. Gülden E, Wong FS, Wen L. The gut microbiota and Type 1 
Diabetes. Clin Immunol. 2015; 159(2):143-53. 
35. Schneeberger M, Everard A, Gómez-Valadés AG, Matamoros 
S, Ramírez S, Delzenne NM, et al. Akkermansia muciniphila 
inversely correlates with the onset of inflammation, altered adipose 
tissue metabolism and metabolic disorders during obesity in mice. 
Sci Rep. 2015;5:16643. 
36. Xu Y, Wang N, Tan HY, Li S, Zhang C, Feng Y. Function of 
Akkermansia muciniphila in Obesity: Interactions With Lipid 
Metabolism, Immune Response and Gut Systems. Front 
Microbiol. 2020; 11:219. 
 
